vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $133.7M, roughly 1.3× FIRST COMMONWEALTH FINANCIAL CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 13.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.
ESPR vs FCF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $133.7M |
| Net Profit | — | $37.5M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 28.1% |
| Revenue YoY | 143.7% | 13.0% |
| Net Profit YoY | — | 14.8% |
| EPS (diluted) | $0.32 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $133.7M | ||
| Q4 25 | $168.4M | $137.9M | ||
| Q3 25 | $87.3M | $136.0M | ||
| Q2 25 | $82.4M | $131.0M | ||
| Q1 25 | $65.0M | $118.0M | ||
| Q4 24 | $69.1M | $120.4M | ||
| Q3 24 | $51.6M | $121.2M | ||
| Q2 24 | $73.8M | $120.2M |
| Q1 26 | — | $37.5M | ||
| Q4 25 | — | $44.9M | ||
| Q3 25 | $-31.3M | $41.3M | ||
| Q2 25 | $-12.7M | $33.4M | ||
| Q1 25 | $-40.5M | $32.7M | ||
| Q4 24 | — | $35.8M | ||
| Q3 24 | $-29.5M | $32.1M | ||
| Q2 24 | $-61.9M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 40.9% | ||
| Q3 25 | -11.4% | 38.1% | ||
| Q2 25 | 8.6% | 32.1% | ||
| Q1 25 | -34.0% | 34.8% | ||
| Q4 24 | -6.4% | 37.1% | ||
| Q3 24 | -31.0% | 33.4% | ||
| Q2 24 | 3.5% | 38.7% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | — | 32.5% | ||
| Q3 25 | -35.9% | 30.4% | ||
| Q2 25 | -15.4% | 25.5% | ||
| Q1 25 | -62.2% | 27.7% | ||
| Q4 24 | — | 29.8% | ||
| Q3 24 | -57.2% | 26.5% | ||
| Q2 24 | -83.9% | 30.9% |
| Q1 26 | — | $0.37 | ||
| Q4 25 | $0.32 | $0.44 | ||
| Q3 25 | $-0.16 | $0.39 | ||
| Q2 25 | $-0.06 | $0.32 | ||
| Q1 25 | $-0.21 | $0.32 | ||
| Q4 24 | $-0.14 | $0.35 | ||
| Q3 24 | $-0.15 | $0.31 | ||
| Q2 24 | $-0.33 | $0.36 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $154.9M |
| Stockholders' EquityBook value | $-302.0M | $1.6B |
| Total Assets | $465.9M | $12.3B |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $154.9M | ||
| Q4 25 | — | $261.7M | ||
| Q3 25 | — | $262.1M | ||
| Q2 25 | — | $262.4M | ||
| Q1 25 | — | $262.7M | ||
| Q4 24 | — | $263.0M | ||
| Q3 24 | — | $136.3M | ||
| Q2 24 | — | $136.6M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $-302.0M | $1.6B | ||
| Q3 25 | $-451.4M | $1.5B | ||
| Q2 25 | $-433.5M | $1.5B | ||
| Q1 25 | $-426.2M | $1.4B | ||
| Q4 24 | $-388.7M | $1.4B | ||
| Q3 24 | $-370.2M | $1.4B | ||
| Q2 24 | $-344.2M | $1.4B |
| Q1 26 | — | $12.3B | ||
| Q4 25 | $465.9M | $12.3B | ||
| Q3 25 | $364.0M | $12.3B | ||
| Q2 25 | $347.1M | $12.2B | ||
| Q1 25 | $324.0M | $11.8B | ||
| Q4 24 | $343.8M | $11.6B | ||
| Q3 24 | $314.1M | $12.0B | ||
| Q2 24 | $352.3M | $11.6B |
| Q1 26 | — | 0.10× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | 0.10× | ||
| Q2 24 | — | 0.10× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $187.5M | ||
| Q3 25 | $-4.3M | $49.5M | ||
| Q2 25 | $-31.4M | $30.4M | ||
| Q1 25 | $-22.6M | $55.9M | ||
| Q4 24 | $-35.0M | $129.5M | ||
| Q3 24 | $-35.3M | $53.6M | ||
| Q2 24 | $-7.2M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $171.5M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $113.9M | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 124.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 94.6% | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 11.7% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 12.9% | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.18× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 0.91× | ||
| Q1 25 | — | 1.71× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | — | 1.67× | ||
| Q2 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
FCF
Segment breakdown not available.
